.png?width=1900&height=550&name=310W25-HERO-EMAIL-FINAL%20(1).png)
Safia Rizvi
CEO
Mark Burns
Director, Marketing Operations
Frank Nazzario
VP, Commercial
.jpg)
Archana Sondhi
Vice President Marketing and Commercial Strategy
Keith White
VP, Commercial
Marina Orlova
Executive Director, Commercial Strategy
Daniela van Eickels, MD, PhD, MPH
Senior Vice President, CMO Head of Medical Affairs
Taylor Salinardi, PhD
VP, Head of Global Medical Affairs role
Carolyn Reever, PhD
Global Head, Neuropsychiatry & Epilepsy Medical Affairs
Amy Everitt, PharmD, MS
Senior Director, Therapeutic Area Lead
Bree Kuntz
Senior Product Manager, HCP Marketing
Sarah Strattman
Global Communications Lead
Caroline Ojaimi
Executive Director, Medical Affairs Operations
Lynn Bass, PharmD
Medical Affairs Lead in Rare Disease Hematology and Cellular Therapy
Noelle Griffin
Global Head Nephrology & Transplant Medical Affairs
Michael Liberman
Senior Medical Director - Pipeline
Tina Rezakhani
US Medical Affairs - Rare Disease (EAST)
Board Member
Helen Chang, RPh
Executive Director, Rare Disease Marketing
Wallace Mondesire, MD
Vice President
5 pages · PDF
Free Event Guide
The complete launch readiness playbook for your team
Speakers, sessions, research insights, and pricing — everything you need to align your cross-functional team on attending.
✓ Instant download
✓ No spam
✓ Share with your team
18+
speakers
2
days
6
key themes
Pfizer BMS Takeda Vertex
8:00 AM
Networking
Registration and Networking Breakfast
8:45 AM
Opening
Opening Remarks
9:00 AM
Keynote
From Clinical Milestones to Commercial Momentum: Building a Seamless Path to Launch
- Translating pivotal trial strategy into a differentiated launch narrative that resonates with regulators, payers, HCPs, and patients
- Identifying critical inflection points during Phase II/III where commercial, medical, and access teams must engage early
- Designing cross-functional governance models that prevent “handoff gaps” between clinical and commercial
- Aligning endpoints, HEOR strategy, and real-world evidence plans to support pricing, reimbursement, and field readiness
- Building internal launch readiness dashboards that integrate clinical progress with operational and commercial KPIs
- Avoiding common pitfalls: late market shaping, misaligned messaging, and siloed decision-making
9:45 AM
Session
Inside the Launch Decision Room: An Interview on the Choices That Make or Break a Product Launch
Go Behind the Scenes of Real Executive Decision-Making During the Critical 12–24 Months Leading Up to Launch
- Explore how leaders prioritize investments, manage risk, and balance speed vs. certainty across Medical, Commercial, and Market Access
- Learn how leadership teams align the entire organization around launch milestones, KPIs, and accountability
- Hear real examples of KOL/HCP impact as well as successful partnerships with disease state associations
- Understand how cross-functional collaboration can break down silos to accelerate readiness
Safia Rizvi
CEO · Cila Therapeutics
10:45 AM
Break
Networking Break
11:15 AM
Panel
From Strategy to Uptake: Building a Commercial Launch Engine That Drives Awareness, Adoption, and Growth
- Translate brand strategy into a launch-ready commercial plan that aligns marketing, sales, market access, and analytics
- Build a scalable pre-launch awareness strategy through segmentation, targeting, and omnichannel engagement
- Design the field readiness model—training, messaging, tools, and KPIs—for confident execution from day one
- Leverage data, AI, and predictive analytics to identify priority audiences and optimize launch performance
- Align commercial messaging with Medical Affairs and Market Access for consistent, differentiated value communication
Frank Nazzario
VP, Commercial · Larimar Therapeutics
Archana Sondhi
VP Marketing & Commercial Strategy · IDEAYA Biosciences
Keith White
VP, Commercial · Disc Medicine
Marina Orlova
Executive Director, Commercial Strategy · Merck
Helen Chang RPh
Executive Director, Rare Disease Marketing · Shionogi
12:30 PM
Break
Networking Lunch
1:30 PM
Session
From Gap to Growth: Building Market Readiness Before Launch Through Disease Awareness, Partnerships, and Real-World Insight
- Identifying healthcare system gaps, unmet needs, and disease recognition opportunities to shape the environment before launch
- Building early disease-state awareness campaigns through education, messaging, and competitive landscape analysis
- Partnering with professional societies, HCP congresses, advisory boards, and strategic collaborators early
- Using market research, patient advisory boards, and RWE to refine messaging and demonstrate impact
2:15 PM
Session
Building the AI-Enabled Launch Engine: Embedding Intelligent Workflows Across Marketing, Sales, and Commercial Operations
- Design scalable marketing and commercial systems for multiple launches, new indications, and reformulations
- Embed AI into core workflows across promotional review, content lifecycle, speaker programs, and campaign execution
- Connect marketing technologies, fulfillment systems, and CRM platforms for a unified launch ecosystem
- Practical strategies for making AI a core operating model to drive measurable commercial launch impact
Mark Burns
Director, Marketing Operations · Avidity Biosciences
2:45 PM
Break
Networking Break
3:15 PM
Session
From Data to Narrative: Communicating Scientific Value to All Stakeholders Before and Beyond Launch
- Transforming clinical data into compelling, compliant narratives that communicate scientific value and differentiation
- Aligning corporate, medical, and commercial messaging across publications, media, investor updates, and launch materials
- Preparing for high-visibility milestones including pivotal data readouts, regulatory decisions, and approval announcements
- Building cross-functional collaboration between Medical Affairs, Corporate Communications, and Commercial teams
Sarah Strattman
Global Communications Lead · Vertex Pharmaceuticals
4:00 PM
Panel
Medical Affairs as the Strategic Launch Engine: Building the Team, Evidence, and Engagement Model for Launch Success
- Define how Medical Affairs leaders can shape launch strategy early by aligning evidence generation and cross-functional decision making
- Build and scale a high-impact Medical Affairs launch team—roles, capabilities, resourcing, and training
- Develop a modern KOL engagement strategy blending traditional thought leaders, rising experts, and digital opinion leaders
- Create a compliant, scalable scientific engagement model that strengthens HCP relationships before, during, and after launch
- Measure Medical Affairs launch impact using clear metrics and dashboards that demonstrate value to leadership
Daniela van Eickels, MD, PhD, MPH
SVP, CMO Head of Medical Affairs · Kyowa Kirin
Taylor Salinardi, PhD
VP, Head of Global Medical Affairs role · SynOx Therapeutics
Carolyn Reever, PhD
Global Head, Neuropsychiatry & Epilepsy Medical Affairs · Biogen
Caroline Ojaimi
Executive Director, Medical Affairs Operations · BioNTech
Anna Murzhenko, PharmD
Medical Affairs Leader
Noelle Griffin
Global Head Nephrology & Transplant Medical Affairs · Biogen
Wallace Mondesaire, MD
Vice President · Revolution Medicines
Natalia Borinshteyn
Former VP, HCV Launch Team, Global and U.S. Medical Affairs, ABBVIE | Founder · Life Science Excellence
5:30 PM
Closing
End of Day One
8:00 AM
Networking
Networking Breakfast
8:45 AM
Opening
Opening Remarks
9:00 AM
Keynote
Commercial Launch Readiness: Aligning Sales, Marketing, Access & Operations for Customer Engagement
- From Insight to Execution: How customer insights shape commercial strategy and influence launch readiness
- Designing the Sales Organization for Launch: Building the right field structure and sales force effectiveness model
- Startup vs. Established Company Launch Models: Table stakes for building commercial infrastructure in emerging biotech
- Market Access Integration: Incorporating payer and provider perspectives early, including HEOR strategy and value evidence
- Driving Customer Engagement at Launch: Aligning commercial teams for meaningful engagement with providers and stakeholders
10:00 AM
Session
Channel Strategy and Trade Readiness: Aligning Market Access, Distribution, and Commercial Execution for Launch
- Designing the right channel model based on product characteristics, patient population, and market access strategy
- Leveraging pre-approval information exchange (PIE) to engage payers early
- Preparing trade and distribution operations including specialty distributor contracts and inventory planning
- Why trade strategy is often the “forgotten child” of launch planning and how to elevate its importance
10:45 AM
Break
Networking Break
11:15 AM
Session
Build Patient-Powered Launches: Strategic Partnerships with Advocacy Groups, Nonprofits & Disease Communities
- Build relationships with patient communities and advocacy organizations 12–24 months pre-launch
- Partner with advocacy groups to co-create education, support programs, and disease awareness initiatives
- Navigate compliance and regulatory considerations while maintaining authentic patient engagement
- Define and track meaningful KPIs to measure patient engagement impact on access, adoption, and outcomes
Tina Rezakhani, PharmD, MBA
US Medical Affairs – Rare Disease | Board Member · Sanofi | Amedea Pharma
12:00 PM
Networking
Networking Lunch
1:00 PM
Panel
From Insight to Impact: Building a Data-Driven Field Engagement Strategy that Drives Launch Success
- Translate field insights from MSLs, KAMs, and field teams into actionable strategy
- Identify and prioritize the right stakeholders including KOLs, community experts, and digital opinion leaders
- Leverage engagement platforms, CRM systems, and insight management tools to capture field intelligence
- Connect field insights back to Medical, Commercial, Market Access, and Evidence Generation teams
Lynn Bass, PharmD
Medical Affairs Lead, Rare Disease Hematology · Mesoblast
Ana Bozas, PhD, CMPP
Medical Affairs & Medical Communications Leader
Sanaz Cardoza
Medical Affairs Strategy Leader
Michael Liberman
Senior Medical Director – Pipeline · Exelixis
2:00 PM
Session
Building Launch Alignment: How Medical Insights Shape Commercial Strategy, Messaging, and Execution
- Early Medical Affairs engagement during Phase III to ensure clinical insights inform commercial launch strategy
- Aligning Medical and Commercial teams around shared disease state education and key data messaging
- Developing speaker bureau and peer-to-peer programs that translate unmet needs into credible HCP education
- Creating a culture that supports cross-functional collaboration through empowerment and recognition
Amy Everitt, PharmD, MS
Senior. Director, Therapeutic Area Lead · Praxis Precision Medicines
2:45 PM
Session
Exchange to Market Momentum: Designing HCP Engagement That Drives Launch Impact
- Translating early Phase III scientific insights into messaging that resonates with HCPs at launch
- Navigating the medical-to-commercial transition while maintaining credibility and scientific integrity
- Engaging KOLs early to shape educational content, disease awareness, and clinical narratives
- Developing scalable speaker bureau programs and field education initiatives that activate quickly at launch
Bree Kuntz
Senior Product Manager, HCP Marketing · Verona Pharmaceuticals
3:30 PM
Closing
Conference Ends
